pointed out that in patients with stage IV NSCLC undergoing EGFR-TKI and stereotactic radiotherapy, only 6.67% developed grade 2 pneumonia, with no observations of grade 3 or higher levels of pulmonary toxicity (41). The gene discussed is EGFR; the disease is pneumonia.